High-profile failures imperilled emerging anticancer MET inhibitors, but trials guided by a new biomarker are beginning to restore confidence.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Journal of Translational Medicine Open Access 01 October 2023
-
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Journal of Experimental & Clinical Cancer Research Open Access 29 March 2022
-
Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
Cellular and Molecular Life Sciences Open Access 05 March 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. MET inhibitors start on road to recovery. Nat Rev Drug Discov 13, 563–565 (2014). https://doi.org/10.1038/nrd4406
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4406
This article is cited by
-
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Journal of Translational Medicine (2023)
-
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Journal of Experimental & Clinical Cancer Research (2022)
-
Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells
Cellular and Molecular Life Sciences (2022)
-
MET targeting: time for a rematch
Oncogene (2020)
-
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
Acta Pharmacologica Sinica (2019)